Ultragenyx, Dimension make deal official

On Oct. 3, rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said it will acquire gene therapy play Dimension Therapeutics Inc. (NASDAQ:DMTX) for $6 per share, or about $151 million. Ultragenyx outbid RegenxBio Inc. (NASDAQ:RGNX), which had agreed to acquire Dimension last month.

Ultragenyx said that the prior deal has been terminated, and that it will pay RegenxBio a $2.9 million termination fee on Dimension's behalf...